{"id":"irinotecan-injection","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"60-70","effect":"Nausea and vomiting"},{"rate":"15-20","effect":"Alopecia"},{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Abdominal pain"},{"rate":"15-25","effect":"Asthenia/fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irinotecan is a camptothecin derivative that inhibits topoisomerase I, an enzyme essential for DNA unwinding and replication. By stabilizing the topoisomerase I-DNA complex, it prevents the religation of DNA strands, causing irreversible DNA damage during the S phase of the cell cycle. This leads to apoptosis in rapidly dividing cancer cells.","oneSentence":"Irinotecan is a topoisomerase I inhibitor that prevents DNA religation during replication, leading to DNA damage and cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:13.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT07483684","phase":"PHASE3","title":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"HER2 IHC3+ Advanced Colorectal Cancer","enrollment":142},{"nctId":"NCT07479732","phase":"PHASE1, PHASE2","title":"Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-03-05","conditions":"Osteosarcoma, Osteosarcoma Metastatic","enrollment":56},{"nctId":"NCT07011576","phase":"PHASE2","title":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-09-29","conditions":"Colon Cancer, Rectal Cancer, Colorectal Cancer","enrollment":60},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT07463573","phase":"PHASE3","title":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04-05","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":466},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT07457775","phase":"PHASE2","title":"Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-31","conditions":"Soft Tissue Sarcoma (Excluding GIST)","enrollment":24},{"nctId":"NCT05846867","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-05-08","conditions":"Colorectal Cancer","enrollment":170},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07085338","phase":"PHASE2","title":"A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-11-10","conditions":"Neuroblastoma Recurrent","enrollment":54},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT07397819","phase":"PHASE1, PHASE2","title":"Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy","status":"RECRUITING","sponsor":"Dong sheng Zhang","startDate":"2025-11-28","conditions":"Malignant Ascites","enrollment":48},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT06351020","phase":"PHASE3","title":"LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","startDate":"2024-06-24","conditions":"Locally Advanced or Metastatic GC and GCJ Adenocarcinoma","enrollment":387},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT07381309","phase":"PHASE2","title":"Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM","status":"NOT_YET_RECRUITING","sponsor":"Jun Huang","startDate":"2026-02-01","conditions":"CRC, Liver Metastasis Colon Cancer","enrollment":114},{"nctId":"NCT07376499","phase":"PHASE2","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2026-01-25","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT07284134","phase":"PHASE3","title":"JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-12-24","conditions":"Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":560},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06375473","phase":"","title":"Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-04-19","conditions":"Pancreatic Cancer","enrollment":3000},{"nctId":"NCT07314385","phase":"PHASE1","title":"NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-01-01","conditions":"Pancreatic Adenocarcinoma Metastatic, Liver Metastasis","enrollment":24},{"nctId":"NCT07235202","phase":"PHASE1, PHASE2","title":"A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy","status":"RECRUITING","sponsor":"Shenzhen Majory Biotechnology Co., Ltd.","startDate":"2025-12-24","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":45},{"nctId":"NCT07309289","phase":"PHASE3","title":"NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":144},{"nctId":"NCT07309185","phase":"PHASE2","title":"Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2024-07-24","conditions":"Stomach Neoplasms","enrollment":66},{"nctId":"NCT04796012","phase":"PHASE1, PHASE2","title":"VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Solid Tumor, Rhabdomyosarcoma","enrollment":23},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT06065371","phase":"PHASE1","title":"Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2024-11-20","conditions":"Gastrointestinal Cancer","enrollment":20},{"nctId":"NCT07289997","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-28","conditions":"AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC","enrollment":39},{"nctId":"NCT07238283","phase":"PHASE3","title":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-02","conditions":"First-line Treatment of Metastatic Pancreatic Cancer","enrollment":662},{"nctId":"NCT04570943","phase":"PHASE2","title":"Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-06-16","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":103},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT05381038","phase":"PHASE1, PHASE2","title":"Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2023-02-13","conditions":"Solid Tumor, Gastrointestinal Cancer, Breast Cancer","enrollment":10},{"nctId":"NCT06258642","phase":"NA","title":"Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-17","conditions":"Small Cell Lung Cancer Recurrent","enrollment":39},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT07123441","phase":"PHASE2","title":"A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sanjun Cai","startDate":"2025-09-01","conditions":"Colorectal Cancer","enrollment":300},{"nctId":"NCT04141995","phase":"PHASE2","title":"FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2021-02-12","conditions":"Pancreas Cancer, Adenocarcinoma of the Pancreas","enrollment":11},{"nctId":"NCT07092306","phase":"PHASE2","title":"A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"Tang Xiaodong","startDate":"2025-08-10","conditions":"Ewing's Sarcoma","enrollment":74},{"nctId":"NCT03806309","phase":"PHASE2","title":"OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2021-04-10","conditions":"Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer","enrollment":106},{"nctId":"NCT07070713","phase":"PHASE2","title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-07-30","conditions":"Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy","enrollment":44},{"nctId":"NCT06199973","phase":"PHASE3","title":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-03-01","conditions":"Advanced Colorectal Cancer","enrollment":130},{"nctId":"NCT07027748","phase":"PHASE1","title":"Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma","status":"RECRUITING","sponsor":"Steven DuBois, MD","startDate":"2025-06-27","conditions":"Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma","enrollment":18},{"nctId":"NCT03693677","phase":"PHASE2","title":"First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-11-16","conditions":"Metastatic Pancreatic Cancer","enrollment":288},{"nctId":"NCT07044921","phase":"PHASE2","title":"Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-09-01","conditions":"Colorectal Cancer Metastatic","enrollment":30},{"nctId":"NCT06954246","phase":"PHASE3","title":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06-04","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":450},{"nctId":"NCT06013618","phase":"PHASE2","title":"Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2023-06-19","conditions":"Neuroblastoma","enrollment":120},{"nctId":"NCT07014540","phase":"PHASE4","title":"A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-06-20","conditions":"Neuroendocrine Carcinomas (NEC)","enrollment":45},{"nctId":"NCT04581473","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection","status":"ACTIVE_NOT_RECRUITING","sponsor":"CARsgen Therapeutics Co., Ltd.","startDate":"2020-10-23","conditions":"Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":192},{"nctId":"NCT06827717","phase":"PHASE2","title":"Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-15","conditions":"Ewing Sarcoma","enrollment":29},{"nctId":"NCT04861558","phase":"PHASE3","title":"Efficacy of Hyperthermic Intraperitoneal Chemotherapy","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2021-05-01","conditions":"Colorectal Cancer, Peritoneal Metastases","enrollment":213},{"nctId":"NCT06992687","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2024-09-01","conditions":"Solid Tumors","enrollment":30},{"nctId":"NCT06993025","phase":"PHASE2","title":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-05-25","conditions":"Biliary Tract Cancer","enrollment":30},{"nctId":"NCT03206151","phase":"PHASE3","title":"CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2017-12-12","conditions":"Metastatic Colorectal Cancer","enrollment":520},{"nctId":"NCT04415853","phase":"PHASE3","title":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-01-21","conditions":"Esophageal Cancer","enrollment":416},{"nctId":"NCT04478292","phase":"PHASE3","title":"A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy","status":"RECRUITING","sponsor":"Shanghai Children's Medical Center","startDate":"2021-03-01","conditions":"Hepatoblastoma","enrollment":330},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT05383352","phase":"PHASE1","title":"A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-05-30","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":177},{"nctId":"NCT06951841","phase":"PHASE4","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-04-30","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT04796948","phase":"PHASE1","title":"A Study of Irinotecan Liposome in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-08","conditions":"Advanced Pancreatic Cancer","enrollment":41},{"nctId":"NCT03468335","phase":"PHASE3","title":"2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-03-31","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":151},{"nctId":"NCT05457829","phase":"PHASE2","title":"Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-30","conditions":"Rhabdomyosarcoma, Child","enrollment":88},{"nctId":"NCT06913218","phase":"PHASE1","title":"A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2025-07-22","conditions":"Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma","enrollment":60},{"nctId":"NCT06766266","phase":"PHASE1","title":"Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-01-10","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma","enrollment":18},{"nctId":"NCT06894797","phase":"NA","title":"Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-04-01","conditions":"Locally Advanced Rectal Cancer","enrollment":68},{"nctId":"NCT06278454","phase":"PHASE1","title":"Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2024-01-09","conditions":"Unresectable Pancreatic Cancer","enrollment":58},{"nctId":"NCT06888648","phase":"PHASE1, PHASE2","title":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-01","conditions":"Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable","enrollment":30},{"nctId":"NCT03088813","phase":"PHASE3","title":"Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ipsen","startDate":"2018-04-25","conditions":"Small Cell Lung Cancer","enrollment":491},{"nctId":"NCT05178745","phase":"","title":"Resection Observatory","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-07","conditions":"Metastatic Colorectal Cancer, Colorectal Neoplasms","enrollment":140},{"nctId":"NCT06643793","phase":"PHASE2","title":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-11-04","conditions":"Colorectal Neoplasms Malignant","enrollment":30},{"nctId":"NCT06572813","phase":"PHASE1, PHASE2","title":"Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-11-15","conditions":"Pancreas Cancer","enrollment":63},{"nctId":"NCT06657690","phase":"PHASE2","title":"Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":56},{"nctId":"NCT03866525","phase":"PHASE1, PHASE2","title":"OH2 Oncolytic Viral Therapy in Solid Tumors","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2019-04-02","conditions":"Solid Tumor, Gastrointestinal Cancer","enrollment":300},{"nctId":"NCT06649292","phase":"PHASE3","title":"SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-11-22","conditions":"Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":524},{"nctId":"NCT06094140","phase":"PHASE2","title":"NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2022-05-20","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT06697366","phase":"PHASE2","title":"Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-20","conditions":"Gastric Cancer","enrollment":27},{"nctId":"NCT06656091","phase":"PHASE3","title":"A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-10-31","conditions":"Advanced Oesophageal Squamous Cell Carcinoma","enrollment":450},{"nctId":"NCT06225999","phase":"PHASE2","title":"Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2024-04-25","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":41},{"nctId":"NCT06603376","phase":"PHASE2","title":"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-09-01","conditions":"Colorectal Carcinoma","enrollment":75},{"nctId":"NCT06577376","phase":"PHASE1, PHASE2","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-08-26","conditions":"Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past","enrollment":252},{"nctId":"NCT04366648","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor","status":"COMPLETED","sponsor":"JenKem Technology Co., Ltd.","startDate":"2018-05-04","conditions":"Solid Tumor","enrollment":25},{"nctId":"NCT02826486","phase":"PHASE2","title":"Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2016-09","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":80},{"nctId":"NCT06486545","phase":"NA","title":"Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2024-08-25","conditions":"Advanced Gastric Cancer","enrollment":18},{"nctId":"NCT06341296","phase":"PHASE2","title":"Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-06-30","conditions":"Metastatic Colorectal Cancer","enrollment":86},{"nctId":"NCT06341309","phase":"PHASE1, PHASE2","title":"Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-08-09","conditions":"Metastatic Colorectal Cancer","enrollment":20},{"nctId":"NCT06531278","phase":"PHASE2","title":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety","status":"RECRUITING","sponsor":"Jiang Long","startDate":"2024-07-16","conditions":"Pancreatic Cancer Metastatic to Liver","enrollment":40},{"nctId":"NCT04728035","phase":"PHASE1","title":"Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance","status":"COMPLETED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-05-31","conditions":"Advanced Breast Cancer","enrollment":119},{"nctId":"NCT06513455","phase":"PHASE1, PHASE2","title":"Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-09-01","conditions":"Pancreatic Cancer","enrollment":132},{"nctId":"NCT06513221","phase":"PHASE2","title":"A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-25","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT06499610","phase":"PHASE4","title":"Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2024-07-15","conditions":"Gastric Cancer","enrollment":44},{"nctId":"NCT05009953","phase":"PHASE2","title":"Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer","status":"TERMINATED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-09-01","conditions":"Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma","enrollment":17},{"nctId":"NCT02352337","phase":"PHASE2","title":"First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-01-12","conditions":"Metastatic Pancreatic Cancer","enrollment":276},{"nctId":"NCT04727853","phase":"PHASE2","title":"Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)","status":"COMPLETED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-03-01","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":66},{"nctId":"NCT02827201","phase":"PHASE2","title":"FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-11","conditions":"Metastatic Pancreatic Cancer","enrollment":127}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"DIARRHOEA"},{"count":5,"reaction":"DEHYDRATION"},{"count":4,"reaction":"HAEMOGLOBIN DECREASED"},{"count":4,"reaction":"HYPONATRAEMIA"},{"count":4,"reaction":"NAUSEA"},{"count":4,"reaction":"VOMITING"},{"count":3,"reaction":"DRUG INTERACTION"},{"count":3,"reaction":"DRUG TOXICITY"},{"count":3,"reaction":"NEUTROPENIA"},{"count":3,"reaction":"PULMONARY EMBOLISM"}],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CAMPTO"],"phase":"phase_3","status":"active","brandName":"Irinotecan Injection","genericName":"Irinotecan Injection","companyName":"Chinese Academy of Medical Sciences","companyId":"chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Irinotecan is a topoisomerase I inhibitor that prevents DNA religation during replication, leading to DNA damage and cancer cell death. Used for Metastatic colorectal cancer, Small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}